MinervaX is a clinical stage, privately owned Danish biopharmaceutical company which is developing an innovative protein-only vaccine for Group B Streptococcus (GBS). This pathogen is the leading cause of life-threatening infections, infection-related deaths and long-term disability in newborns during the first 3 months of life. A vaccine for GBS is highly needed to avoid an estimated 150.000 preventable stillbirths and infant deaths every year.